You are here

Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?

Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?

Submitted by admin on October 19, 2023 - 11:29am

Source:

Medical Marketing and Media

News Tags:

EGFR-mutated NSCLC

Headline:

Could J&J’s Rybrevant-based combo disrupt AstraZeneca’s Tagrisso in lung cancer faceoff?

snippet:

J&J’s Rybrevant-based combo could take share from AstraZeneca’s Tagrisso in EGFR-mutant lung cancer, initial data suggest. Just how much will be the subject of debate.